Nano-satellite complexes

Patent metadata

Field	Value
Publication number	US-12226491-B2
Application number	US-202117232751-A
Country	US
Kind code	B2
Filing date	Apr 16, 2021
Priority date	Oct 17, 2018
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1).

First claim

We claim:

1. A composition comprising: a nano-satellite complex, wherein said nano-satellite complex surface has a negative charge, and wherein said nano-satellite complex comprises:
a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core;
b) 10-20 gold satellite particles attached to, or absorbed to, said biocompatible coating;
c) a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and
d) wherein said nano-satellite complex comprises all of the following properties:
i) wherein the weight-to-weight ratio of all of said satellite particles to said nanoparticle core is 10-40%;
ii) wherein the diameter of each of said satellite particles is 1-5 nm, and the diameter of the nano-satellite complex is 20-70 nm;
iii) wherein said plurality of antigenic peptides is 1500-2500 antigenic peptides;
iv) wherein 100-225 of said plurality of said antigenic peptides are present on each of said satellite particles; and
v) wherein the average distance between each of said satellite particles is 4-7 nm.

2. The composition of claim 1 , further comprising an immune checkpoint inhibitor.

3. The composition of claim 1 , wherein said core nanoparticle comprises Fe 3 O 4 .

4. The composition of claim 1 , wherein said biocompatible coating comprises polysiloxane.

5. The composition of claim 1 , wherein said antigenic peptide comprises: i) a neoantigenic determinant, ii) at least one epitope from a tumor antigen, iii) at least one epitope from a viral oncoprotein, iv) a least one epitope from an infectious virus, v) at least one epitope from a parasite, or vi) at least one epitope from an infectious bacteria.

6. A method of eliciting an immune response in a subject comprising: administering to a subject said composition of claim 1 .

7. The method of claim 6 , wherein said subject is a human.

8. The method of claim 6 , wherein said subject is administered a type I interferon agonist agent, either in said composition or separately.

9. The method of claim 6 , wherein said subject is administered an immune checkpoint inhibitor, either in said composition or separately.

Assignees

• Univ Michigan Regents

Inventors

• Sun Duxin
• Clauson Ryan
• Chen Hongwei
• Li Chengyi
• Gao Wei
• Bugada Luke
• Wen Fei
• Hill Brett
• Rizvi Syed Monem

Classifications

• A61K40/4205

  Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4 · CPC title

• A61K40/24

  Antigen-presenting cells [APC] · CPC title

• A61K40/13

  B-cells · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/49

  Breast · CPC title